Trial reportCancer reports (Hoboken, N.J.)2026
Botulinum Toxin (Dysport) to Prevent Radiation-Induced Dysfunction of Salivary Glands in Head and Neck Cancer.
Trial report in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe main goal of this pilot trial was to investigate the efficacy of botulinum toxin (Dysport) injection before radiotherapy in preserving salivary gland secretion in patients with head and neck cancer.
methodsSixteen patients with head and neck cancer were enrolled, 9 received 50 IU Dysport, and 7 recieved NaCl (0.9%) into the submandibular glands before chemo-radiotherapy. To investigate the salivary gland function, technetium pertechnetate salivary gland scintigraphy, as well as saliva accumulation and the University of Washington Quality of Life (UW-QoL) Questionnaire were utilized "before" and "6 months after the end" of radiotherapy.
resultsSixteen patients were randomized (9 botulinum toxin, 7 placebo). Baseline characteristics were comparable between groups. At 6 months post-radiotherapy, basal saliva volume was higher in the botulinum toxin group (median 5.0 cc vs. 2.0 cc; p < 0.001) as was stimulated saliva volume (6.0 cc vs. 2.0 cc; p < 0.001). UW-QoL scores were significantly lower, indicating better quality of life, in the botulinum toxin group (37.0 vs. 67.0; p < 0.001). Covariate-adjusted analyses confirmed botulinum toxin as the only significant predictor of saliva preservation and improved QoL.
conclusionA single injection of botulinum toxin before radiotherapy preserves salivary gland function and improves quality of life. Based on these findings, we advocate for a multicenter Phase II trial to define the optimal dose-response relationship and determine the ideal timing for injection relative to the start of radiotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.